

Press release

Zug, 4 January 2010

HBM BioVentures sells Ziemer Group investment

HBM BioVentures has sold its investment in the Ziemer Group. The sale yielded CHF 7 million in cash, which will be used in part for follow-on financings of other promising companies in the HBM BioVentures portfolio.

Together with another shareholder, HBM BioVentures Ltd has sold its investment in the privately-held Ziemer Group Ltd (Port, Switzerland) for CHF 7 million to other existing Ziemer Group shareholders. The sale price corresponds to the book value at which HBM BioVentures has carried the investment for over two years.

The Ziemer Group specialises in the development and sale of systems and equipment to treat eye diseases. HBM BioVentures first invested in the medtech company in 2001, providing it with considerable support for eight years, including a further round of financing in 2005. (www.ziemergroup.com)

For further information, please contact Dr. Andreas Wicki, CEO HBM BioVentures Ltd, tel.: +41 41 768 11 08, andreas.wicki@hbmbioventures.com.

HBM BioVentures Ltd

As a venture capital company, HBM BioVentures is invested globally in some 35 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The lead products of many of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unlisted emerging companies, with two-thirds of assets being invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN). Visit www.hbmbioventures.com.

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug / Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hbmbioventures.com
www.hbmbioventures.com